Fundraising Fox

Sophia Genetics

Founded 2011 · 506 employees on LinkedIn · 7 known investors

SOPHiA GENETICS develops the SOPHiA DDM data analytics platform for genomic and multimodal data analysis, offering solutions used in oncology research and in vitro diagnostics. Its products serve clinical and research institutions, with several CE-IVD diagnostic solutions available across Europe, the UK, Switzerland, and Israel.

AI & Machine LearningBiotechDigital HealthMedical Devices

Investors · 7

360 CapitalMilan · $162K – $10.8M
aMoonRa'anana
Balderton CapitalLondon · $5M – $50M
CompoundNew York · $400K – $1.5M
Hitachi VenturesMunich
Invoke CapitalLondonvia Mike Lynch · inferred
ACE & CompanyreportedNew Yorkvia Sherif El Halwagy · inferred

In the news

BTIG raises Sophia Genetics stock price target on CDx deals By Investing.cominvesting.com · Aug 2026Sophia Genetics earnings missed by $0.07, revenue topped estimates By Investing.comca.investing.com · Aug 2026SOPH Stock Heads For Best Day In Over 8 Months – What’s Driving Today’s Super Rally?stocktwits.com · Aug 2026Sophia Genetics Inks CDx Collaboration With AstraZeneca as Q2 Revenue Jumps 27 Percent | GenomeWebgenomeweb.com · Aug 2026Sophia Genetics bags $77M Series E, with 850+ hospitals signed uptechcrunch.com · Jan 2019

Frequently asked questions

What does Sophia Genetics do?
SOPHiA GENETICS develops the SOPHiA DDM data analytics platform for genomic and multimodal data analysis, offering solutions used in oncology research and in vitro diagnostics. Its products serve clinical and research institutions, with several CE-IVD diagnostic solutions available across Europe, the UK, Switzerland, and Israel.
Who are Sophia Genetics's investors?
Sophia Genetics's investors include 360 Capital, aMoon, Balderton Capital, Compound, Hitachi Ventures, Invoke Capital, ACE & Company.